HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Acumen Pharmaceuticals (NASDAQ:ABOS) and maintained a $15 price target.
July 17, 2023 | 10:19 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Acumen Pharmaceuticals' stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $15.
The reiteration of a 'Buy' rating and maintained price target by a reputable analyst firm like HC Wainwright & Co. is a positive signal for Acumen Pharmaceuticals. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100